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Nils E. Magnusson, PHD‡§
Copenhagen and Aarhus, Denmark
Objectives The aim of this study was to investigate the prognostic role of neutrophil gelatinase–associated lipocalin (NGAL)
in a large population of patients with ST-segment elevation myocardial infarction.
Background NGAL is a glycoprotein released by damaged renal tubular cells and is a sensitive maker of both clinical and
subclinical acute kidney injury. New data have demonstrated that NGAL is also stored in granules of mature neu-
trophils, and recent data suggest that NGAL may also be involved in the development of atherosclerosis. NGAL is
significantly increased in patients with myocardial infarction compared with patients with stable coronary artery
disease and healthy subjects. However, the prognostic value of NGAL has never been studied in patients with
myocardial infarction.
Methods We included 584 consecutive ST-segment elevation myocardial infarction patients admitted to the heart
center of Gentofte University Hospital, Denmark, and treated with primary percutaneous coronary interven-
tion, from September 2006 to December 2008. Blood samples were drawn immediately before primary
percutaneous coronary intervention. Plasma NGAL levels were measured using a time-resolved immunofluo-
rometric assay. The endpoints were all-cause mortality (n  69) and the combined endpoints (n  116) of
major adverse cardiac events (MACE) defined as cardiovascular mortality and admission due to recurrent
myocardial infarction or heart failure. The median follow-up time was 23 months (interquartile range, 20 to
24 months).
Results Patients with high NGAL (75th percentile) had increased risk of all-cause mortality and MACE compared with
patients with low NGAL (log-rank test, p  0.001). After adjustment for confounding risk factors chosen by back-
ward elimination by Cox regression analysis, high NGAL remained an independent predictor of all-cause mortal-
ity and MACE (hazard ratio: 2.00; 95% confidence interval: 1.16 to 3.44; p  0.01 and hazard ratio: 1.51;
95% confidence interval: 1.00 to 2.30; p  0.05, respectively).
Conclusions High plasma NGAL independently predicts all-cause mortality and MACE in ST-segment elevation myocardial
infarction patients treated with primary percutaneous coronary intervention. (J Am Coll Cardiol 2012;60:
339–45) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.017a
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NGAL and STEMI July 24, 2012:339–45cells, smooth muscle cells, and mac-
rophages in atherosclerotic plaques
(3) and that NGAL may be in-
volved in the development of ath-
erosclerosis via endothelial dysfunc-
tion, inflammatory processes, and
matrix degradation (3–5), leading to
atherosclerotic plaque instability by
modulating the activity of metallo-
proteinase 9 (4). Plasma NGAL is
significantly increased in the pres-
ence of coronary artery disease
(CAD) and correlates with its sever-
ity (6); furthermore, plasma NGAL
is significantly higher in patients
with acute myocardial infarction
(AMI) compared with stable CAD
(7). This leads to the hypothesis that
NGAL, a widely accepted renal
marker, may be a prognostic marker
in patients with AMI. We therefore
investigated the prognostic utility
of NGAL in patients with ST-
segment elevation myocardial in-
farction (STEMI) treated with
primary percutaneous coronary
intervention (pPCI).
ethods
tudy population. From September 2006 through Decem-
er 2008, we prospectively enrolled 584 STEMI patients
reated with pPCI at Gentofte University Hospital, Copen-
agen, Denmark. Inclusion criteria were patients admitted
ue to a suspected STEMI with the presence of chest pain
or 30 min and 12 h, and persistent ST-segment
levation 2 mm in at least 2 contiguous precordial
lectrocardiography leads or 1 mm in at least 2 contiguous
imb electrocardiography leads or a newly developed left
undle branch block. Exclusion criteria were a nonsignifi-
ant troponin I increase (0.5 g/l), percutaneous coronary
ntervention (PCI) was not performed (no stenoses on
oronary artery angiography or coronary artery bypass sur-
ery was elected instead) or missing NGAL values. A total
f 1,030 patients met the inclusion criteria. However, 446
atients were excluded due to exclusion criteria, thus ending
p with 584 STEMI patients.
Gentofte University Hospital is a high-volume center at
hich 1,500 PCIs are performed yearly. A description of
he PCI setting and procedure at Gentofte University
ospital was previously published (8). Subsequent medical
reatment included aspirin 75 mg daily, clopidogrel 75 mg
aily (for 12 months), lipid-lowering drugs (statins), and
-receptor antagonists.
Information on both height and weight was collected for
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
AKI  acute kidney injury
AMI  acute myocardial
infarction
CAD  coronary artery
disease
CRP  C-reactive protein
CV  cardiovascular
eGFR  estimated
glomerular filtration rate
MACE  major adverse
cardiovascular event(s)
NGAL  neutrophil
gelatinase–associated
lipocalin
PCI  percutaneous
coronary intervention
pPCI  primary
percutaneous coronary
intervention
STEMI  ST-segment
elevation myocardial
infarctionall patients to calculate the body mass index and estimatedglomerular filtration rate (eGFR). We defined hypertension
as use of blood pressure–lowering drugs on admission.
Patients were considered to have type 2 diabetes mellitus if
they were being treated with glucose-lowering drugs at the
time of admission or had a fasting plasma glucose concen-
tration 7 mmol/l or a nonfasting plasma glucose concen-
tration 11.1 mmol/l. Patients were considered to have
hypercholesterolemia if they were being treated with
cholesterol-lowering drugs at the time of admission. Mul-
tivessel disease was defined as 2- or 3-vessel-disease and
complex lesions such as type C lesions. Severe hemody-
namic stress was defined as the need for vasopressors or an
intra-aortic balloon pump, and severe bradyarrhythmia or
cardiac arrest treated with basic life support and/or defibril-
lation. Echocardiography was performed by specialists at
our institution in 305 patients (52%) using Vivid 7 or E9
(GE Vingmed Ultrasound, Horten, Norway) 1 to 2 days
after admission. The left ventricular ejection fraction was
visually estimated by expert interpreters guided by strain
analyses and wall motion index. The accuracy of this
method was documented previously (9).
Endpoints were all-cause mortality and major adverse car-
diovascular events (MACE) defined as cardiovascular (CV)
mortality or admission due to recurrent AMI or heart failure.
Follow-up information with regard to the endpoints was
obtained after 23 months (interquartile range, 20 to 24).
Information was obtained for all 584 patients from the
National Person Identification Registry, hospital sources,
and data from the highly validated Danish National Board
of Health’s National Patient Registry (10). The study was
approved by the local scientific ethical committee and The
Danish Data Protection Agency and complied with the
second revision of the Declaration of Helsinki.
Laboratory methods. Blood samples were drawn from the
femoral sheath before the pPCI procedure (baseline values).
Serum was centrifuged within 30 min and plasma stored at
80°C for subsequent analysis.
Plasma NGAL was determined using an in-house time-
resolved immunofluorometric assay based on NGAL anti-
bodies and recombinant NGAL from R&D Systems
(Abingdon, United Kingdom) (11). Samples and controls
were diluted 1:100 and analyzed in duplicate. Intra-assay
coefficients of variation of standards, controls, unknown
samples, and nonspecific background controls averaged
5%. Interassay coefficients of variation averaged 9%
based on standards, nonspecific background controls, inter-
nal controls, and repeated samples. Plasma NGAL concen-
trations were determined using a 5-parameter standard
curve fit implemented in the WorkOut 2.5 Data Analysis
software (Perkin Elmer Inc., Waltham, Massachusetts).
Mean values were calculated and used for statistical analyses.
Other blood tests including C-reactive protein (CRP),
troponin I, and creatinine were assayed by routine laboratory
methods. Troponin I was measured at baseline and after 6 and
12 h. Creatinine was measured at baseline. In patients remain-
ing at our institution for post-PCI treatment (53%, n  309),
p
i
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July 24, 2012:339–45 NGAL and STEMIcreatinine was measured again on the second and third days
and again if deemed necessary. eGFR was estimated on the
basis of serum creatinine (at baseline), age, sex, and weight
using the Cockcroft-Gault formula (12).
Statistical analysis. Plasma NGAL concentrations were
ositively skewed and therefore logarithmically transformed
n the statistical analysis where appropriate. In Table 1,
omparisons between groups were performed using the 2
test for dichotomous variables, the Student t test if Gaussian
distributed, and Mann-Whitney U test if non-Gaussian
distributed. Kaplan-Meier curves according to high versus
low NGAL (cutoff at the 75th percentile) were constructed
and compared by the log-rank test. The association of
NGAL with endpoints was examined by Cox proportional
hazards regression analyses both in univariate and multivar-
iate models including selected variables identified using
backward elimination. Variables were entered as listed in
Table 1. To maintain a robust model, only 1 variable for
each 10 events was allowed in the final models. Evaluation
of first-order interactions was done after selecting the final
model, and interactions were tested both in models contain-
ing 1 variable and NGAL and in a model containing all the
selected variables. Deviation from linearity was assessed by
simultaneous assessment of linear and quadratic effects.
Misspecification of the functional form of the covariates and
Baseline Clinical Characteristics of STEMI PatiepPCI Stratified According to High NGAL (>75 hTable 1 Baseline Clinical Characteristics ofpPCI Stratified According to High N
Age, y
Male, %
Hypertension, %
Diabetes, %
Current smoker, %
Hypercholesterolemia, %
Previous myocardial infarction, %
Body mass index, kg/m2
Peak troponin I, g/l
C-reactive protein, mg/l
Serum creatinine, mol/l
Estimated glomerular filtration rate, ml/min
Further increased serum creatinine during
admission, %
Increase in serum creatinine during admission
in patients with further increased creatinine
during admission, mol/l
Symptom-to-balloon time, min
Left ventricular ejection fraction (available in
52% [n  305])
Complex lesion, %
Multivessel disease, %
LAD lesion
Glycoprotein IIb/IIIa inhibitor
Severe hemodynamic stress before PCI
Values are % for categorical variables, mean  SD for Gaussian, and
LAD  left anterior descending coronary artery; NGAL  neutrophil gelatin
pPCI  primary percutaneous coronary intervention; STEMI  ST-segment elthe assumption of proportional hazards were evaluated by
plots of the cumulative martingale residuals. For the statis-
tical analysis, p values 0.05 were considered of statistical
significance. SPSS for Windows version 20.0 (SSPS Inc.,
Chicago, Illinois) and SAS software (SAS for Windows,
version 9.2, SAS Institute Inc., Cary, North Carolina) were
used.
Results
Distribution of NGAL and baseline characteristics.
During follow-up (median, 23 months; interquartile range,
20 to 24 months), all-cause mortality was 12% (n  69),
including 7% (n  38) from CV causes. Six percent of
patients (n  36) were admitted to the hospital with a new
AMI and 9% (n  55) due to heart failure. Nineteen
percent (n  116) reached the combined endpoint of
MACE.
The plasma level of NGAL was (geometric mean [5th to
95th percentiles]) 134.2 g/l (range, 44.9 to 400.6 g/l).
High NGAL was significantly associated with age, current
smoking, CRP, creatinine, and severe hemodynamic stress
and inversely associated with eGFR (Table 1). No interac-
tions between NGAL and baseline variables with regard to
endpoints were found.
reated byentil ) Versus Low NGALI Patients Treated by
(>75th Percentile) Versus Low NGAL
NGAL
.1 g/l
438)
High NGAL
>170.1 g/l
(n  146) p Value
 12 66 13 0.002
73 73 0.95
32 36 0.38
8 13 0.08
54 42 0.02
16 23 0.06
6 8 0.16
 4.6 26.4 6.7 0.64
1–244) 94 (30–283) 0.47
–8) 6 (3–18) 0.001
 30 137 99 0.001
 21 59 26 0.001
26 21 0.09
–20) 18 (4–28) 0.40
30–310) 195 (135–315) 0.74
0–50) 35 (28–45) 0.07
49 51 0.63
26 30 0.33
44 50 0.21
29 23 0.22
9 24 0.001
and interquartile range for non-Gaussian distributed variables.nts TPercSTEM
GAL
Low
<170
(n 
62
26.6
114 (3
3 (1
91
78
11 (5
195 (1
40 (3
median
ase–associated lipocalin; PCI  percutaneous coronary intervention;
evated myocardial infarction.
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NGAL and STEMI July 24, 2012:339–45NGAL and mortality/MACE. The log-rank test based on
the Kaplan-Meier curves showed a significant association
between high NGAL (75th percentile) and all-cause
mortality (p  0.001) (Fig. 1A) and MACE (p  0.001)
Fig. 1B). After adjustment for selected baseline variables
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Figure 1 NGAL and All-Cause Mortality and MACE
(A) Kaplan-Maier plots of all-cause mortality dependent on neutrophil gelatinase-
associated lipocalin (NGAL) stratified as high (75th percentile) versus low.
(B) Kaplan-Maier plot of major adverse cardiac events (MACE) for NGAL strati-
fied as high versus low. PCI  percutaneous coronary intervention.listed in Table 2), using Cox regression analyses, high
g
TGAL remained a significantly independent predictor of
ll-cause mortality and MACE (Table 2).
As seen in Figure 1B, a large proportion of the CV events
ccurred in the first 30 days after the STEMI. This is in
ccord with previous studies of patients with STEMI (13).
atients with early events had higher NGAL than patients
ith events occurring after 30 days (geometric mean [5th to
5th percentiles]: 192.2 g/l (range, 48.2 to 764.4 g/l) vs.
132.7 g/l (range, 50.4 to 349.3 g/l) (p  0.001).
NGAL, kidney function, and AKI. Two patients were
treated with long-term hemodialysis before their STEMI;
no other patients were treated with dialysis during admis-
sion. Patients with high NGAL had increased creatinine
and decreased eGFR at admission. In patients with high
NGAL, increasing creatinine during admission did not
occur more frequently and creatinine did not increase
significantly during admission compared with patients with
low NGAL (Table 1), although this might be difficult to
interpret due to the fact that nephrotoxic contrast was used
during the PCI, possibly influencing an increase in creati-
nine during admission.
Increased NGAL is associated with the occurrence of
both clinical and subclinical AKI, and the increase occurs
before creatinine making adjustment for AKI difficult
(14,15).
However, to reduce the influence of potential AKI, we
adjusted the Cox regression analyses for severe hemody-
namic stress before the PCI. As seen in Table 2, high
NGAL remained an independent predictor of both all-
cause mortality and MACE after this adjustment.
Furthermore, we evaluated the impact of increased cre-
atinine during admission with respect to endpoints. In
univariate models, increased creatinine during admission
was associated with all-cause mortality (p  0.04) but not
MACE (p  0.56). When included in the multivariate Cox
regression analyses, increased creatinine during admission
did not predict all-cause mortality (p  0.67) or MACE
(p  0.50). In fact, the variable was eliminated early by
backward elimination, and when it was included in the
model, increased creatinine levels did not affect the prog-
nostic value of NGAL.
Multivariable Cox Analyses Estimating HRfor High NGAL (Upper Quartile [170.1 g/l])Table 2 Multivari ble Cox An lyses Estimating HRfor High NGAL (Upper Quartile [170.1 g/l])
HR 95% CI p Value
All-cause mortality (n  69), adjusted forage,
BMI, CRP, eGFR, peak TnI, and severe
hemodynamic stress
2.00 1.16–3.44 0.01
MACE (n  116), adjusted for age, previous AMI,
BMI, CRP, eGFR, peak TnI, symptom-to-
balloon time, multivessel disease, use of
glycoprotein IIb/IIIa inhibitor, and severe
hemodynamic stress
1.51 1.00–2.30 0.05
BMI  body mass index; CI  confidence interval; CRP  C-reactive protein; eGFR  estimated
lomerular filtration rate; HR  hazard ratio; NGAL  neutrophil gelatinase–associated lipocalin;
nI  troponin I; MACE  major cardiovascular event(s); AMI  acute myocardial infarction.
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July 24, 2012:339–45 NGAL and STEMINGAL and CRP. There were no interactions between
NGAL and CRP with regard to reaching the endpoints.
Using a cutoff at the 75th percentile for NGAL (170.1 g/l)
and the upper limit of normal of CRP (10 mg/l) (16),
patients were stratified by high/low NGAL and high/low
CRP. Table 3 shows a Cox regression analysis for all-cause
ortality including the 4 groups. When both markers were
igh, risk was significantly increased (hazard ratio: 6.6; 95%
onfidence interval: 3.5 to 12.2; p  0.001). Figure 2A
shows Kaplan-Meier curves for the 4 groups. As shown,
patients with high NGAL/high CRP had the poorest
outcome, whereas low NGAL/low CRP had the best.
Likewise, Figure 2B shows that the risk of MACE was high
when NGAL was high regardless of CRP, whereas the risk
was low when NGAL was low.
Discussion
The present study demonstrates for the first time that high
NGAL is an independent predictor of all-cause mortality
and CV events in patients with STEMI treated with pPCI,
even after adjusting for conventional risk factors, renal
function, and other significant baseline values. We were able
to confirm previous findings of an association between
NGAL and CV risk factors such as age and current smoking
(17). However, we did not find an association between
NGAL and the number of affected coronary arteries, which
was previously described (6).
The primary cause of coronary artery thrombosis and
acute coronary syndrome (ACS) (including STEMI) is
rupture of atherosclerotic plaque (18,19). Inflammation
plays a role in the pathogenesis of atherosclerosis and plaque
instability and thus ACS (20). It has been demonstrated
that CRP and neutrophil leukocytes increase in the event of
ACS and that neutrophils infiltrate the atherosclerotic
plaques and is involved in the inflammatory process leading
to plaque rupture (21–23). Expression of NGAL is also
increased in atherosclerotic plaques (3), and in combination
with the correlation with the CV risk factors, age, hyper-
tension, and smoking (17), NGAL may be directly involved
in the development and progression of atherosclerosis and
CAD. Indeed Zografos et al. (6) found that NGAL was
independently associated with the presence and severity of
CAD in 73 patients undergoing coronary angiography. This
was also found by Choi et al. (24) in a study of 49 patients
with CAD compared with 42 age- and sex-matched con-
Cox Models for Risk of All-Cause Mortalityin Groups Based on NGAL and CRPTable 3 Cox Models for Ri k of All-Cause Mortalityin Groups Based on NGAL and CRP
All-Cause Mortality HR 95% CI p Value
NGAL 170.1, CRP 10 (n  363) 1.00 —
NGAL 170.1, CRP 10 (n  76) 2.48 1.20–5.12 0.014
NGAL 170.1, CRP 10 (n  86) 3.63 1.93–6.84 0.001
NGAL 170.1, CRP 10 (n  59) 6.46 3.50–11.95 0.001
Abbreviations as in Table 2.trols. In a study of 128 patients with CAD (37 stable CAD,37 non-STEMI, 53 STEMI), NGAL was higher in pa-
tients with AMI compared with stable CAD (7).
The prognostic value of NGAL is well established in
renal disorders (25), but it has not been investigated in
patients with AMI until now. Recent data have demon-
strated that in the instance of acute heart failure, NGAL
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Figure 2 All-Cause Mortality and MACE
Based on NGAL and CRP
Kaplan-Meier plots of all-cause mortality (A) and MACE (B) based on cutoffs of
170.1 g/l for NGAL and 10 mg/l for C-reactive protein (CRP). Abbreviations
as in Figure 1.
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NGAL and STEMI July 24, 2012:339–45was a strong predictor of 30-day heart failure rehospitaliza-
tion and all-cause mortality, far more than brain natriuretic
peptide, creatinine, and eGFR (26). This association was
also found by Alvelos et al. (27) in a study of 121 patients
with acute heart failure. We were able to extend the
prognostic value of NGAL to patients with AMI (STEMI).
It is tempting to speculate that part of the prognostic
information of NGAL is related to its association with
inflammation, as Ramos-Mozo et al. (28) have shown that
NGAL is a marker of thrombus activity, but the prognostic
value could likely be explained by the well-established
relationship between increased NGAL and AKI (29) be-
cause AKI is common in critically ill patients (30).
In a large multicenter analysis of critically ill patients,
Haase et al. (30) demonstrated that increased NGAL was
associated with both poorer outcomes and increased need
for renal replacement therapy and therefore likely represents
subclinical AKI. Several other studies have also shown that
increased NGAL is associated with AKI, although sensitiv-
ity and specificity were only moderate (14,15).
The relationship between increased NGAL and AKI is
also evident in the present study in which high NGAL is
strongly associated with increased creatinine, reduced
eGFR, and more frequent severe hemodynamic stress before
admission and thus likely AKI.
We found no association between high NGAL and
increased creatinine during admission; however, creatinine
is an insensitive marker of AKI (30), and the use of
nephrotoxic contrast during PCI makes interpretation dif-
ficult. Therefore, elevated NGAL levels may still represent
subclinical AKI.
To demonstrate a possible association between NGAL
and endpoints independent of AKI, we adjusted our anal-
yses for both eGFR, further increased creatinine during
admission, and severe hemodynamic stress before the pPCI
(and thus likely AKI). That high NGAL remained an
independent predictor of all-cause mortality and MACE
could suggest a nonrenal contribution to plasma NGAL.
However, due to limitations in the study design, this
adjustment may be insufficient.
NGAL exists in different molecular forms and Cai et al.
(31) suggested that monomeric and heterodimeric forms are
the predominant forms produced by tubular epithelial cells,
whereas the dimeric form primarily originates from neutro-
phils. Further investigation is therefore needed before firm
conclusions about the origin of NGAL can be drawn.
CRP is involved in vascular inflammation by its inhibi-
tion of nitric oxide (32) and was previously shown to predict
mortality in patients with ACS (33). In this study, patients
with increased CRP and probably vascular inflammation
had increased mortality. However, the combination of high
CRP/high NGAL significantly conferred the highest mor-
tality, whereas low CRP/low NGAL conferred the lowest
mortality; thus, NGAL conferred additional prognostic
information. Of interest, patients with high NGAL/low
CRP had a higher risk of mortality compared with patientswith low NGAL/high CRP, thus indicating that NGAL
possesses better prognostic value compared with CRP.
With regard to MACE, patients with high NGAL had
significantly increased risk regardless of CRP.
NGAL was higher in patients with early events compared
with patients with events occurring later. This could indi-
cate a relationship with vascular inflammation, but this
point needs to be investigated further.
Study limitations. The present study demonstrates an
independent prognostic value of NGAL in patients with
STEMI; however, it cannot prove a causal relationship with
CAD. Therefore, investigations of the source(s) and specific
molecular forms of increased NGAL in patients with ACS
are warranted. Timing of blood samples is an issue in the
few studies investigating NGAL and CAD. We measured
NGAL just before the invasive procedure to prevent con-
tamination with contrast fluid and increase in NGAL due to
direct tissue damage of the kidney (i.e., ischemia-
reperfusion injury caused by the pPCI) (34). However, we
only measured NGAL and other inflammatory markers
once. It is possible that additional blood sampling as
inflammation peaked would have provided a more accurate
correlation with other inflammatory markers, as done by
Sahinarslan et al. (7). In contrast, Choi et al. (24) measured
NGAL 3 months after coronary angiography. To evaluate
the prognostic value of NGAL independently of AKI,
baseline creatinine levels before admission would be needed
to make a true assessment of AKI. Furthermore, urine
NGAL levels compared with plasma NGAL levels would
have been useful. Finally, this study was conducted as a
single-center study.
Conclusions
High NGAL independently predicts all-cause mortality and
MACE after AMI. Whether this is caused by AKI,
increased inflammation, or both and whether plaque rupture
contributes as well remain to be elucidated.
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